A Multicenter, Open-Label, Randomized Trial of Vonoprazan Versus PPI Based 7-Day Triple Therapy for the First-Line Treatment of Helicobacter Pylori Infection

therapy, H. pylori eradication was achieved in 112 patients (99.1%).The overall rate of grade 2 side effects was 2.9%.The side effects included nausea and diarrhea (1.01%), abdominal pain (0.67%), skin rash (0.67%), heartburn (0.56%), vomiting (0.22%), and constipation (0.22%).There was no distinct difference in rate of side effects between first line therapy and second line therapy.Eradication rate was not significantly different between age groups (<65, 65-74, >74 years) or genders.Conclusions: Our data demonstrate that vonoprazan-based triple therapy is an effective and relatively safe treatment for H. pylori infection.